Strongbridge Biopharma plc Announces Participation in Two Upcoming Investor Conferences

DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will participate in fireside chats at the Stifel and Jefferies 2020 Virtual Healthcare Conferences.

Details for the presentations are as follows:

The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com

Corporate & Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com

Staff

Recent Posts

Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or…

1 hour ago

cbdMD Announces Additional Conversions of Its Convertible Notes

Charlotte, North Carolina--(Newsfile Corp. - January 8, 2025) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

4 hours ago

This Holiday Season, RXNT Employees Gave Back to Impactful Charities

RXNT celebrated the holiday season by giving back to four worthy, community-driven charities, all with…

4 hours ago

Therap Services Strengthens Documentation with Advanced HIPAA-Compliant Secure Video Documentation Tool

TORRINGTON, Conn., Jan. 8, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

4 hours ago

This Tech at CES 2025 Might Make Your New Year’s Resolution a Reality

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- Could this be the year your fitness goals…

4 hours ago

Net Health Acquires Alinea Engage to Further Optimize Patient Engagement and Outcomes in Rehab Therapy

Investment will advance Net Health's mission to provide patient-centric care by streamlining administrative processes for…

4 hours ago